Loading
Prokidney Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Apr 2025.
Prokidney Corp.: what insiders have been doing
Every trade that managers of Prokidney Corp. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 3 insiders have disclosed 12 filings since 18 October 2025.
The flow runs one way only: 7 sales worth €1.5M, from 1 insider, and no purchase. One trade stands out by size: a sale of €535k from Pereira Brian JG, disclosed on 14 November 2025.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 12 filings here. Our records for Prokidney Corp. go back to 2021, with 10 purchases and 27 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
57
Thresholds
n/a
Buy Volume
€71M
10 ops. · all time
Sell Volume
€20M
27 ops. · all time
Who traded when
BuySaleBrian JG Pereira7 sales
Empresarial de Capitales S.A. de C.V. Control5 buys
Darin J. Weber1 sale
Since the insiders bought
- +82.4%Entry US$1.02 · Close at T+365 US$1.86
- -66.2%Entry US$2.92 · Close at T+365 US$0.99
- -15.1%Entry US$9.84 · Close at T+365 US$8.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.61
Analyst consensus
6 analysts2.00/5
US$1.00Target US$6.25(+288%)US$12.00
Income statement
RevenueUS$893k
EBITDA-US$144.6M-16195% margin
Net income-US$69M-7725.2% margin
Valuation
PER (forward)-2.7x
Beta1.75
Balance sheet & cash
Market capUS$642.7M
Total debtUS$4M
Free Cash Flow-US$135.3M
Debt / Equity2%
Profitability & ownership
ROE-59.0%
ROA-35.7%
% insiders46.5%
% institutions26.4%
Last declaration on 20 August 2026
Declarations57 total
27,051 shares@ US$1.44070.0060% mcap2.3% of flowClass A Common StockSEC:0001193125-26-359349:3
229,338 shares@ US$1.37120.048% mcap18.7% of flowClass A Common StockSEC:0001193125-26-359349:0
27,826 shares@ US$1.37120.0059% mcap2.3% of flowClass A Common StockSEC:0001193125-26-359349:1
222,949 shares@ US$1.44070.049% mcap19.1% of flowClass A Common StockSEC:0001193125-26-359349:2
222,948 shares@ US$1.41990.048% mcap18.6% of flowClass A Common StockSEC:0001193125-26-359349:4
27,052 shares@ US$1.41990.0059% mcap2.3% of flowClass A Common StockSEC:0001193125-26-359349:5
81,929 shares@ US$1.39140.017% mcap10.8% of flowCommonSEC144:0001628280-26-057710
675,235 shares@ US$1.400.14% mcap89.2% of flowCommonSEC144:0001628280-26-057713
81,929 shares0Class A Common StockSEC:0001193125-26-336856:0
675,235 shares0Class A Common StockSEC:0001193125-26-336856:1
63,118,645 shares0Class A Common Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-26-018234:0
227,431 shares@ US$2.723336.8% of flowClass A Common StockSEC:0001193125-25-282922:0
103,480 shares@ US$3.0258.2% of flowClass A Common StockSEC:0000950170-25-094797:0
3,823,996 shares0Class A Ordinary SharesSEC:0000950170-25-082342:0
387,393 shares@ US$0.71341.2% of flowClass A Ordinary Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-25-015444:0
Canonical exit: 21 Jul 2025 (T+90)
25,000 shares@ US$0.74760.1% of flowClass A Ordinary Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-25-014756:0
Canonical exit: 16 Jul 2025 (T+90)
100,000 shares@ US$0.74820.3% of flowClass A Ordinary Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-25-014571:0
Canonical exit: 15 Jul 2025 (T+90)
268,105 shares@ US$0.72580.9% of flowClass A Ordinary Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-25-014211:0
Canonical exit: 13 Jul 2025 (T+90)
1,032,218 shares@ US$0.60812.8% of flowClass A Ordinary Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-25-013770:0
Canonical exit: 9 Jul 2025 (T+90)
81,928 shares0Class A Ordinary SharesSEC:0000950170-25-015369:0
532,535 shares0Class A Ordinary SharesSEC:0000950170-25-015495:0
16,412 shares@ US$2.508.0% of flowClass A Ordinary SharesSEC:0000950170-24-108438:0
81,928 shares0Class A Ordinary SharesSEC:0000950170-24-089935:0
826 shares@ US$2.500.4% of flowClass A Ordinary SharesSEC:0000950170-24-087273:0
8,264,462 shares@ US$2.4294.3% of flowClass A Ordinary Shares (as defined in Exhibit 99.1 hereto)SEC:0001140361-24-031298:0
Canonical exit: 9 Sept 2024 (T+90)
25 of 57 declarations
About Prokidney Corp.
ProKidney Corp. is a clinical-stage biopharmaceutical company listed on the NASDAQ stock market in the United States. Headquartered in Winston-Salem, North Carolina, the company is focused on developing cell therapies for chronic kidney disease (CKD), a progressive condition with significant unmet medical need and a high burden on healthcare systems. Founded in 2015 after a decade of research, ProKidney has built its strategy around a differentiated approach: using a patient’s own kidney cells in an autologous therapy intended to preserve kidney function, slow disease progression, and in some cases improve renal function. Its lead product candidate is rilparencel, also known as REACT®, a patented proprietary cell therapy being evaluated in patients with advanced CKD and diabetes, a population at elevated risk of kidney failure. The company states that the program has received RMAT designation from the FDA, which is notable from a regulatory standpoint.
From a business perspective, ProKidney remains a pure-play biotechnology company with no marketed product revenue at this stage, so value creation depends primarily on clinical, regulatory, and manufacturing milestones. Its core business line is the clinical development of rilparencel, with a Phase 3 program underway in the United States. The company also emphasizes cGMP manufacturing capabilities, which are critical for an autologous cell therapy model. ProKidney has invested in manufacturing infrastructure in North Carolina, reflecting the importance of scalable production ahead of any potential launch.
Read moreShow less
Competitively, ProKidney operates in a highly specialized niche at the intersection of nephrology and regenerative medicine. Its investment case rests on the possibility of being among the first companies to bring a meaningful cell-therapy option to CKD patients. That said, the profile remains inherently high risk, as is typical for clinical-stage biotech companies: trial outcomes, FDA requirements, manufacturing complexity, and capital needs all remain key variables.
Recent developments point to a company preparing for commercialization. In March 2026, ProKidney expanded its senior leadership team with the appointment of Greg Madison as Chief Commercial Officer, indicating that management is building out go-to-market capabilities. The company’s investor communications also referenced first-quarter 2026 results and full-year 2025 business highlights in May and March 2026, respectively, while continuing to frame rilparencel as the central long-term value driver. For French-speaking investors, ProKidney offers exposure to a U.S.-listed NASDAQ biotech story in the United States, with significant upside potential but a materially elevated clinical and execution risk profile.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
